title: Plasma vitronectin polymorphism in normal subjects and patients with disseminated intravascular coagulation.
abstract: Vitronectin, also known as serum-spreading factor or S-protein, mediates cell adhesion and inhibits formation of the membrane-lytic complex of complement and the rapid inactivation of thrombin by antithrombin III in the presence of heparin. Vitronectin is normally present in plasma at a concentration of approximately 300 micrograms/mL. The investigators quantified plasma vitronectin with an enzyme-linked immunosorbent assay and visualized reduced and nonreduced vitronectin by immunoblotting after separation of plasma or serum by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The concentration of plasma vitronectin was markedly reduced in some patients with disseminated intravascular coagulation, especially in those with liver failure; it was near normal in patients with metastatic cancer and acute leukemia. Patients with vitronectin levels less than 40% normal invariably had low fibrinogen and antithrombin III and a prolonged prothrombin time. In both normal and patient plasmas there was heterogeneity in the ratio of the 75,000- and 65,000-mol wt polypeptides of reduced vitronectin: 18% had mostly the 75,000-mol wt polypeptide, 59% had roughly equal amounts of the two polypeptides, and 22% had mostly the 65,000-mol wt polypeptide. This polymorphism is inherited and appears to be due to two alleles that are present with approximately equal frequency. The blotting patterns of vitronectin in reduced and nonreduced plasmas were largely unaltered in plasma of patients with defibrination syndrome, fibrinolysis, liver failure, sepsis, metastatic cancer, and acute leukemia. There was no evidence of fragmentation of vitronectin or formation of the disulfide-bonded complex of vitronectin and thrombin-antithrombin III that is found when blood is clotted. Thus these results corroborate in vitro observations that the liver is the major source of plasma vitronectin, suggest that vitronectin may become depleted during disseminated intravascular coagulation, and define a genetic polymorphism of vitronectin.
authors: Department of Medicine, University of Wisconsin, Madison 53706.
authors: M G
authors: MG
authors: Conlan
authors: B R
authors: BR
authors: Tomasini
authors: R L
authors: RL
authors: Schultz
authors: D F
authors: DF
authors: Mosher
mesh_terms: D000818:Animals; D000990:Antithrombin III / Q000032:analysis; D003101:Collodion; D004211:Disseminated Intravascular Coagulation / Q000097:blood* / Q000235:genetics; D004591:Electrophoresis, Polyacrylamide Gel; D004797:Enzyme-Linked Immunosorbent Assay; D005340:Fibrinogen / Q000032:analysis; D006023:Glycoproteins / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification*; D006801:Humans; D007118:Immunoassay; D008107:Liver Diseases / Q000097:blood / Q000235:genetics; D051379:Mice; D008970:Molecular Weight; D011110:Polymorphism, Genetic; D019096:Vitronectin
chemical_list: D006023:Glycoproteins; D019096:Vitronectin; D000990:Antithrombin III; D005340:Fibrinogen; D003101:Collodion